The fine line between protection and pathology in neurotropic flavivirus and alphavirus infections

Future Virology

Volumn 9, Issue 3, 2014, Pages 313-330

  Ong, Ruo Yan ^a   Lum, Fok Moon ^a,b   Ng, Lisa F P ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

alphavirus; arbovirus; encephalitis; flavivirus; immunity; pathogenesis

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA INTERFERON; CAPSID PROTEIN; CYTOTOXIC FACTOR; ENVELOPE PROTEIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; MACROPHAGE MIGRATION INHIBITION FACTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PERFORIN; STAT1 PROTEIN; STAT2 PROTEIN; STRUCTURAL PROTEIN; TOLL LIKE RECEPTOR 3; VIRUS RNA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ALPHAVIRUS INFECTION; ANTIGEN PRESENTATION; ASTROCYTE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELLULAR IMMUNITY; CHIKUNGUNYA ALPHAVIRUS; DENGUE VIRUS; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; ENCEPHALITIS; ENDOTHELIUM CELL; FLAVIVIRUS INFECTION; GAMMA DELTA T LYMPHOCYTE; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INNATE IMMUNITY; JAPANESE ENCEPHALITIS VIRUS; MICROGLIA; MOLECULAR RECOGNITION; MONOCYTE; MOTONEURON; NATURAL KILLER CELL; NERVE CELL; NEUROLOGIC DISEASE; NEUTROPHIL; NONHUMAN; O NYONG NYONG VIRUS; PARASITE VECTOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ROSS RIVER ALPHA VIRUS; T LYMPHOCYTE; TIGHT JUNCTION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRAL CLEARANCE; VIRAL TROPISM; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

EID: 84899532487     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.6     Document Type: Review

References (190)

1. Weaver SC, Barrett AD. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat. Rev. Microbiol. 2(10), 789-801 (2004).
2. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 371(9611), 500-509 (2008).
3. Sips GJ, Wilschut J, Smit JM. Neuroinvasive flavivirus infections. Rev. Med. Virol. 22(2), 69-87 (2012).
4. Strauss JH, Strauss EG. The alphaviruses: Gene expression, replication, and evolution. Microbiol. Rev. 58(3), 491-562 (1994).
5. Weissenbck H, Hublek Z, Bakonyi T, Nowotny N. Zoonotic mosquito-borne flaviviruses: Worldwide presence of agents with proven pathogenicity and potential candidates of future emerging diseases. Vet. Microbiol. 140(3-4), 271-280 (2010).
6. Atkins GJ. The pathogenesis of alphaviruses. ISRN Virology 2013, 22 (2013).
7. Griffin D. Alphaviruses, flaviviruses, and bunyaviruses. In Neuropathogenic Viruses and Immunity. Specter S, Bendinelli M, Friedman H (Eds). Springer, NY, USA, 255-274 (1992).
8. Medigeshi GR. Mosquito-borne flaviviruses: Overview of viral life-cycle and host-virus interactions. Future Virol. 6(9), 1075-1089 (2011).
9. Keller BC, Fredericksen BL, Samuel MA et al. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J. Virol. 80(19), 9424-9434 (2006).
10. Liu WJ, Wang XJ, Mokhonov VV, Shi PY, Randall R, Khromykh AA. Inhibition of interferon signaling by the New York strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79(3), 1934-1942 (2005).
11. Suthar MS, Diamond MS, Gale M Jr. West Nile virus infection and immunity. Nat. Rev. Microbiol. 11(2), 115-128 (2013).
12. Wilson JR, De Sessions PF, Leon MA, Scholle F. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J. Virol. 82(17), 8262-8271 (2008).
13. Teng TS, Kam YW, Tan JJ, Ng LF. Host response to Chikungunya virus and perspectives for immune-based therapies. Future Virol. 6(8), 975-984 (2011).
14. Kielian M. Structural biology: An alphavirus puzzle solved. Nature 468(7324), 645-646 (2010).
15. Snyder JE, Kulcsar KA, Schultz KL et al. Functional characterization of the alphavirus TF protein. J. Virol. 87(15), 8511-8523 (2013).
16. Uchime O, Fields W, Kielian M. The role of E3 in pH protection during alphavirus assembly and exit. J. Virol. 87(18), 10255-10262 (2013).
17. Suhrbier A, Jaffar-Bandjee MC, Gasque P. Arthritogenic alphaviruses-an overview. Nat. Rev. Rheumatol. 8(7), 420-429 (2012).
18. Monath TP. Yellow fever. Medicine 33(7), 21-23 (2005).
19. Steele KE, Twenhafel NA. Review paper : Pathology of animal models of alphavirus encephalitis. Vet. Pathol. 47(5), 790-805 (2010).
20. Zacks MA, Paessler S. Encephalitic alphaviruses. Vet. Microbiol. 140(3-4), 281-286 (2010).
21. Economopoulou A, Dominguez M, Helynck B et al. Atypical Chikungunya virus infections: Clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Reunion. Epidemiol. Infect. 137(4), 534-541 (2009).
22. Lebrun G, Chadda K, Reboux AH, Martinet O, Gazre BA. Guillain-Barre syndrome after chikungunya infection. Emerg. Infect. Dis. 15(3), 495-496 (2009).
23. Fazakerley JK. Pathogenesis of Semliki Forest virus encephalitis. J. Neurovirol. 8(Suppl. 2), 66-74 (2002).
24. Mathiot CC, Grimaud G, Garry P et al. An outbreak of human Semliki Forest virus infections in Central African Republic. Am. J. Trop. Med. Hyg. 42(4), 386-393 (1990).
25. Willems WR, Kaluza G, Boschek CB et al. Semliki Forest virus: Cause of a fatal case of human encephalitis. Science 203(4385), 1127-1129 (1979).
26. Murthy JM. Neurological complication of dengue infection. Neurol. India 58(4), 581-584 (2010).
27. Solomon T, Dung NM, Vaughn DW et al. Neurological manifestations of dengue infection. Lancet 355(9209), 1053-1059 (2000).
28. Varatharaj A. Encephalitis in the clinical spectrum of dengue infection. Neurol. India 58(4), 585-591 (2010).
29. Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop. Med. Int. Health 12(9), 1087-1095 (2007).
30. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: The spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10(Suppl. 12), S98-S109 (2004).
31. Solomon T. Flavivirus encephalitis. N. Engl. J. Med. 351(4), 370-378 (2004).
32. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. Venezuelan equine encephalitis. Annu. Rev. Entomol. 49, 141-174 (2004).
33. Petersen LR, Roehrig JT. West Nile virus: A reemerging global pathogen. Emerg. Infect. Dis. 7(4), 611-614 (2001).
34. Bai F, Kong KF, Dai J et al. A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J. Infect. Dis. 202(12), 1804-1812 (2010).
35. Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J. Invest. Dermatol. 114(3), 560-568 (2000).
36. Lim PY, Behr MJ, Chadwick CM, Shi PY, Bernard KA. Keratinocytes are cell targets of West Nile virus in vivo. J. Virol. 85(10), 5197-5201 (2011).
37. Samuel MA, Whitby K, Keller BC et al. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80(14), 7009-7019 (2006).
38. MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74(2), 914-922 (2000).
39. Misra UK, Kalita J. Overview: Japanese encephalitis. Prog. Neurobiol. 91(2), 108-120 (2010).
40. Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J. Neurol. Neurosurg. Psychiatry 68(4), 405-415 (2000).
41. Davis NL, Brown KW, Greenwald GF et al. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212(1), 102-110 (1995).
42. Vogel P, Abplanalp D, Kell W et al. Venezuelan equine encephalitis in BALB/c mice: Kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch. Pathol. Lab. Med. 120(2), 164-172 (1996).
43. Samuel MA, Wang H, Siddharthan V, Morrey JD, Diamond MS. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc. Natl Acad. Sci USA 104(43), 17140-17145 (2007).
44. Hunsperger EA, Roehrig JT. Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice. J. Neurovirol. 12(2), 129-139 (2006).
45. Samuel MA, Diamond MS. Pathogenesis of West Nile Virus infection: A balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80(19), 9349-9360 (2006).
46. Getts DR, Terry RL, Getts MT et al. Ly6c+ inflammatory monocytes are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J. Exp. Med. 205(10), 2319-2337 (2008).
47. Klein RS, Diamond MS. Immunological headgear: Antiviral immune responses protect against neuroinvasive West Nile virus. Trends Mol. Med. 14(7), 286-294 (2008).
48. Myint KS, Raengsakulrach B, Young GD et al. Production of lethal infection that resembles fatal human disease by intranasal inoculation of macaques with Japanese encephalitis virus. Am. J. Trop. Med. Hyg. 60(3), 338-342 (1999).
49. Schfer A, Brooke CB, Whitmore AC, Johnston RE. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J. Virol. 85(20), 10682-10690 (2011).
50. Schfer A, Whitmore AC, Konopka JL, Johnston RE. Replicon particles of Venezuelan equine encephalitis virus as a reductionist murine model for encephalitis. J. Virol. 83(9), 4275-4286 (2009).
51. Charles PC, Walters E, Margolis F, Johnston RE. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 208(2), 662-671 (1995).
52. Mishra MK, Dutta K, Saheb SK, Basu A. Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: Correlation with minocycline administration as a therapeutic agent. Neurochem. Int. 55(8), 717-723 (2009).
53. Arjona A, Foellmer HG, Town T et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J. Clin. Invest. 117(10), 3059-3066 (2007).
54. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10(12), 1366-1373 (2004).
55. Yu X, Lin SG, Huang XR et al. Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J. Interferon Cytokine Res. 27(2), 103-109 (2007).
56. Verma S, Kumar M, Gurjav U, Lum S, Nerurkar VR. Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology 397(1), 130-138 (2010).
57. Wang P, Dai J, Bai F et al. Matrix metalloproteinase facilitates West Nile virus entry into the brain. J. Virol. 82(18), 8978-8985 (2008).
58. Dai J, Wang P, Bai F, Town T, Fikrig E. Icam-1 participates in the entry of West Nile virus into the central nervous system. J. Virol. 82(8), 4164-4168 (2008).
59. Liu YF, Teng CL, Liu K. Cerebral cysticercosis as a factor aggravating Japanese B encephalitis. Chin. Med. J. 75(12), 1010-1017 (1957).
60. Shankar SK, Rao TV, Mruthyunjayanna BP, Gourie Devi M, Deshpande DH. Autopsy study of brains during an epidemic of Japanese encephalitis in Karnataka. Indian J. Med. Res. 78, 431-440 (1983).
61. Liu TH, Liang LC, Wang CC, Liu HC, Chen WJ. The blood-brain barrier in the cerebrum is the initial site for the Japanese encephalitis virus entering the central nervous system. J. Neurovirol. 14(6), 514-521 (2008).
62. Dropulic B, Masters CL. Entry of neurotropic arboviruses into the central nervous system: An in vitro study using mouse brain endothelium. J. Infect. Dis. 161(4), 685-691 (1990).
63. Liou ML, Hsu CY. Japanese encephalitis virus is transported across the cerebral blood vessels by endocytosis in mouse brain. Cell Tissue Res. 293(3), 389-394 (1998).
64. Verma S, Lo Y, Chapagain M et al. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier. Virology 385(2), 425-433 (2009).
65. McMinn PC. The molecular basis of virulence of the encephalitogenic flaviviruses. J. Gen. Virol. 78(Pt 11), 2711-2722 (1997).
66. Hasegawa H, Yoshida M, Shiosaka T, Fujita S, Kobayashi Y. Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice. Virology 191(1), 158-165 (1992).
67. Ni H, Barrett AD. Molecular differences between wild-type Japanese encephalitis virus strains of high and low mouse neuroinvasiveness. J. Gen. Virol. 77(Pt 7), 1449-1455 (1996).
68. Beasley DW, Whiteman MC, Zhang S et al. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage West Nile virus strains. J. Virol. 79(13), 8339-8347 (2005).
69. Kim JM, Yun SI, Song BH et al. A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. J. Virol. 82(16), 7846-7862 (2008).
70. Mori Y, Okabayashi T, Yamashita T. Nuclear localization of Japanese encephalitis virus core protein enhances viral replication. J. Virol. 79(6), 3448-3458 (2005).
71. Melian EB, Hinzman E, Nagasaki T et al. NS1 of flaviviruses in the Japanese encephalitis virus serogroup is a product of ribosomal frameshifting and plays a role in viral neuroinvasiveness. J. Virol. 84(3), 1641-1647 (2010).
72. Ubol S, Tucker PC, Griffin DE, Hardwick JM. Neurovirulent strains of Alphavirus induce apoptosis in bcl-2-expressing cells: Role of a single amino acid change in the E2 glycoprotein. Proc. Natl Acad. Sci. USA 91(11), 5202-5206 (1994).
73. Gyure KA. West Nile virus infections. J. Neuropathol. Exp. Neurol. 68(10), 1053-1060 (2009).
74. Van Marle G, Antony J, Ostermann H et al. West Nile virus-induced neuroinflammation: Glial infection and capsid protein-mediated neurovirulence. J. Virol. 81(20), 10933-10949 (2007).
75. Kumar S, Kalita J, Saxena V. Some observations on the tropism of Japanese encephalitis virus in rat brain. Brain Res. 1268, 135-141 (2009).
76. Schoneboom BA, Fultz MJ, Miller TH, McKinney LC, Grieder FB. Astrocytes as targets for Venezuelan equine encephalitis virus infection. J. Neurovirol. 5(4), 342-354 (1999).
77. Unni SK, Rek D, Chhatbar C, Mishra R, Johri MK, Singh SK. Japanese encephalitis virus: From genome to infectome. Microbes Infect. 13(4), 312-321 (2011).
78. Sharma S, Mathur A, Prakash V, Kulshreshtha R, Kumar R, Chaturvedi UC. Japanese encephalitis virus latency in peripheral blood lymphocytes and recurrence of infection in children. Clin. Exp. Immunol. 85(1), 85-89 (1991).
79. King NJ, Getts DR, Getts MT, Rana S, Shrestha B, Kesson AM. Immunopathology of flavivirus infections. Immunol. Cell Biol. 85(1), 33-42 (2007).
80. Ramos HJ, Lanteri MC, Blahnik G et al. IL-1beta signaling promotes CNS-intrinsic immune control of West Nile virus infection. PLoS Pathog. 8(11), e1003039 (2012).
81. Town T, Bai F, Wang T et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 30(2), 242-253 (2009).
82. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202(8), 1087-1098 (2005).
83. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
84. Borden EC, Sen GC, Uze G et al. Interferons at age 50: Past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6(12), 975-990 (2007).
85. Chang TH, Liao CL, Lin YL. Flavivirus induces interferon-beta gene expression through a pathway involving RIG-Idependent IRF-3 and PI3K-dependent NF-kappaB activation. Microbes Infect. 8(1), 157-171 (2006).
86. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M Jr. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J. Virol. 82(2), 609-616 (2008).
87. Daffis S, Samuel MA, Suthar MS, Gale M Jr, Diamond MS. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 82(21), 10349-10358 (2008).
88. Aleyas AG, George JA, Han YW et al. Functional modulation of dendritic cells and macrophages by Japanese encephalitis virus through MyD88 adaptor molecule-dependent and-independent pathways. J. Immunol. 183(4), 2462-2474 (2009).
89. Sharma A, Maheshwari RK. Oligonucleotide array analysis of Toll-like receptors and associated signalling genes in Venezuelan equine encephalitis virus-infected mouse brain. J. Gen. Virol. 90(Pt 8), 1836-1847 (2009).
90. Wang T, Scully E, Yin Z et al. IFN-gammaproducing gamma delta T cells help control murine West Nile virus infection. J. Immunol. 171(5), 2524-2531 (2003).
91. Welte T, Lamb J, Anderson JF, Born WK, OBrien RL, Wang T. Role of two distinct gammadelta T cell subsets during West Nile virus infection. FEMS Immunol. Med. Microbiol. 53(2), 275-283 (2008).
92. Gupta N, Lomash V, Rao PV. Expression profile of Japanese encephalitis virus induced neuroinflammation and its implication in disease severity. J. Clin. Virol. 49(1), 4-10 (2010).
93. Saxena V, Mathur A, Krishnani N, Dhole TN. Kinetics of cytokine profile during intraperitoneal inoculation of Japanese encephalitis virus in BALB/c mice model. Microbes Infect. 10(10-11), 1210-1217 (2008).
94. Salmaggi A, Gelati M, Dufour A et al. Expression and modulation of IFN-gammainducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: Possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J. Interferon Cytokine Res. 22(6), 631-640 (2002).
95. Saxena V, Mathur A, Krishnani N, Dhole TN. An insufficient anti-inflammatory cytokine response in mouse brain is associated with increased tissue pathology and viral load during Japanese encephalitis virus infection. Arch. Virol. 153(2), 283-292 (2008).
96. Kumar P, Sulochana P, Nirmala G, Chandrashekar R, Haridattatreya M, Satchidanandam V. Impaired T helper 1 function of nonstructural protein 3-specific T cells in Japanese patients with encephalitis with neurological sequelae. J. Infect. Dis. 189(5), 880-891 (2004).
97. Grieder FB, Davis BK, Zhou XD, Chen SJ, Finkelman FD, Gause WC. Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus. Virology 233(2), 302-312 (1997).
98. Grieder FB, Vogel SN. Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology 257(1), 106-118 (1999).
99. Schoneboom BA, Catlin KM, Marty AM, Grieder FB. Inflammation is a component of neurodegeneration in response to Venezuelan equine encephalitis virus infection in mice. J. Neuroimmunol. 109(2), 132-146 (2000).
100. Schoneboom BA, Lee JS, Grieder FB. Early expression of IFN-alpha/beta and iNOS in the brains of Venezuelan equine encephalitis virusinfected mice. J. Interferon Cytokine Res. 20(2), 205-215 (2000).
101. Lin RJ, Chang BL, Yu HP, Liao CL, Lin YL. Blocking of interferon-induced JAK-STAT signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatasemediated mechanism. J. Virol. 80(12), 5908-5918 (2006).
102. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4), 778-809 (2001).
103. Harinasuta C, Wasi C, Vithanomsat S. The effect of interferon on Japanese encephalitis virus in vitro. Southeast Asian J. Trop. Med. Public Health 15(4), 564-568 (1984).
104. Isaacs A, Westwood MA. Duration of protective action of interferon against infection with West Nile virus. Nature 184(Suppl. 16), 1232-1233 (1959).
105. Porterfield JS. A simple plaque inhibition test for antiviral agents: Application to assay of interferon. Lancet 274(7098), 326-327 (1959).
106. Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79(21), 13350-13361 (2005).
107. Suthar MS, Ma DY, Thomas S et al. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog. 6(2), e1000757 (2010).
108. Kajaste-Rudnitski A, Mashimo T, Frenkiel MP, Gunet JL, Lucas M, Desprs P. The 2,5-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J. Biol. Chem. 281(8), 4624-4637 (2006).
109. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Positional cloning of the murine flavivirus resistance gene. Proc. Natl Acad. Sci. USA 99(14), 9322-9327 (2002).
110. Szretter KJ, Brien JD, Thackray LB, Virgin HW, Cresswell P, Diamond MS. The interferon-inducible gene viperin restricts West Nile virus pathogenesis. J. Virol. 85(22), 11557-11566 (2011).
111. Chan YL, Chang TH, Liao CL, Lin YL. The cellular antiviral protein viperin is attenuated by proteasome-mediated protein degradation in Japanese encephalitis virus-infected cells. J. Virol. 82(21), 10455-10464 (2008).
112. Gilfoy FD, Mason PW. West Nile virusinduced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR. J. Virol. 81(20), 11148-11158 (2007).
113. Teng TS, Foo SS, Simamarta D et al. Viperin restricts chikungunya virus replication and pathology. J. Clin. Invest. 122(12), 4447-4460 (2012).
114. Schoggins JW, Rice CM. Interferonstimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1(6), 519-525 (2011).
115. Schoggins JW, Wilson SJ, Panis M et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344), 481-485 (2011).
116. Atasheva S, Akhrymuk M, Frolova EI, Frolov I. New PARP gene with an anti-alphavirus function. J. Virol. 86(15), 8147-8160 (2012).
117. Vivier E, Raulet DH, Moretta A et al. Innate or adaptive immunity The example of natural killer cells. Science 331(6013), 44-49 (2011).
118. Zhang M, Daniel S, Huang Y et al. Anti-West Nile virus activity of in vitro expanded human primary natural killer cells. BMC Immunol. 11, 3 (2010).
119. Shrestha B, Samuel MA, Diamond MS. CD8+ T cells require perforin to clear West Nile virus from infected neurons. J. Virol. 80(1), 119-129 (2006).
120. Sooryanarain H, Ayachit V, Gore M. Activated CD56(+) lymphocytes (NK+NKT) mediate immunomodulatory and anti-viral effects during Japanese encephalitis virus infection of dendritic cells in-vitro. Virology 432(2), 250-260 (2012).
121. Crichlow R, Bailey J, Gardner C. Cerebrospinal fluid neutrophilic pleocytosis in hospitalized West Nile virus patients. J. Am. Board Fam. Pract. 17(6), 470-472 (2004).
122. Poccia F, Agrati C, Martini F, Capobianchi MR, Wallace M, Malkovsky M. Antiviral reactivities of gammadelta T cells. Microbes Infect. 7(3), 518-528 (2005).
123. Selin LK, Santolucito PA, Pinto AK, Szomolanyi-Tsuda E, Welsh RM. Innate immunity to viruses: Control of vaccinia virus infection by gamma delta T cells. J. Immunol. 166(11), 6784-6794 (2001).
124. Shrestha B, Wang T, Samuel MA et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80(11), 5338-5348 (2006).
125. Diamond MS, Shrestha B, Mehlhop E, Sitati E, Engle M. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol. 16(3), 259-278 (2003).
126. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J. Virol. 78(15), 8312-8321 (2004).
127. Griffin D, Levine B, Tyor W, Ubol S, Desprs P. The role of antibody in recovery from alphavirus encephalitis. Immunol. Rev. 159, 155-161 (1997).
128. Leake CJ, Burke DS, Nisalak A, Hoke CH. Isolation of Japanese encephalitis virus from clinical specimens using a continuous mosquito cell line. Am. J. Trop. Med. Hyg. 35(5), 1045-1050 (1986).
129. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77(4), 2578-2586 (2003).
130. Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J. Virol. 77(24), 12941-12949 (2003).
131. Hammon WM, Sather GE. Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am. J. Trop. Med. Hyg. 22(4), 524-534 (1973).
132. Camenga DL, Nathanson N, Cole GA. Cyclophosphamide-potentiated West Nile viral encephalitis: Relative influence of cellular and humoral factors. J. Infect. Dis. 130(6), 634-641 (1974).
133. Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J. Infect. Dis. 151(6), 1093-1099 (1985).
134. Nagata LP, Wong JP, Hu W, Wu JQ. Vaccines and therapeutics for the encephalitic alphaviruses. Future Virol. 8(7), 661-674 (2013).
135. Jia L, Zheng A, Yu Y. Study on the immune mechanism of JE attenuated live vaccine (SA14-14-12 strain) in immune inhibited mice. Chin. J. Immunol. Microbiol. 12, 364 (1992).
136. Biswas SM, Ayachit VM, Sapkal GN, Mahamuni SA, Gore MM. Japanese encephalitis virus produces a CD4+ Th2 response and associated immunoprotection in an adoptive-transfer murine model. J. Gen. Virol. 90(Pt 4), 818-826 (2009).
137. Nathanson N, Cole GA. Fatal Japanese encephalitis virus infection in immunosuppresed spider monkeys. Clin. Exp. Immunol. 6(1), 161-166 (1970).
138. Yu Y, Wang J, Zhang G, Li H. Response of normal and athymic mice to infection by virulent and attenuated Japanese encephalitis viruses.Chin. J. Virol. 1, 203-209 (1985).
139. Paessler S, Yun NE, Judy BM et al. Alphabeta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. Virology 367(2), 307-323 (2007).
140. Pan CH, Chen HW, Huang HW, Tao MH. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: Requirement for antibody but not CD8(+) cytotoxic T-cell responses. J. Virol. 75(23), 11457-11463 (2001).
141. Kennedy RC, Shearer MH, Watts AM, Bright RK. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res. 63(5), 1040-1045 (2003).
142. Tishon A, Lewicki H, Andaya A, McGavern D, Martin L, Oldstone MB. CD4 T cell control primary measles virus infection of the CNS: Regulation is dependent on combined activity with either CD8 T cells or with B cells: CD4, CD8 or B cells alone are ineffective. Virology 347(1), 234-245 (2006).
143. Sitati EM, Diamond MS. CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J. Virol. 80(24), 12060-12069 (2006).
144. Liu T, Chambers TJ. Yellow fever virus encephalitis: Properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J. Virol. 75(5), 2107-2118 (2001).
145. Stohlman SA, Hinton DR, Parra B, Atkinson R, Bergmann CC. CD4 T cells contribute to virus control and pathology following central nervous system infection with neurotropic mouse hepatitis virus. J. Virol. 82(5), 2130-2139 (2008).
146. Brien JD, Uhrlaub JL, Nikolich-Zugich J. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J. Immunol. 181(12), 8568-8575 (2008).
147. Brooke CB, Schfer A, Matsushima GK, White LJ, Johnston RE. Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection. J. Gen. Virol. 93(Pt 4), 797-806 (2012).
148. Yun NE, Peng BH, Bertke AS et al. CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus. Vaccine 27(30), 4064-4073 (2009).
149. Larena M, Regner M, Lee E, Lobigs M. Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis. J. Virol. 85(11), 5446-5455 (2011).
150. Aleyas AG, Han YW, George JA et al. Multifront assault on antigen presentation by Japanese encephalitis virus subverts CD8+ T cell responses. J. Immunol. 185(3), 1429-1441 (2010).
151. Shrestha B, Diamond MS. Fas ligand interactions contribute to CD8+ T-cellmediated control of West Nile virus infection in the central nervous system. J. Virol. 81(21), 11749-11757 (2007).
152. Shrestha B, Pinto AK, Green S, Bosch I, Diamond MS. CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. J. Virol. 86(17), 8937-8948 (2012).
153. Brien JD, Uhrlaub JL, Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J. Immunol. 37(7), 1855-1863 (2007).
154. Wang Y, Lobigs M, Lee E, Mllbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 77(24), 13323-13334 (2003).
155. Lanteri MC, OBrien KM, Purtha WE et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J. Clin. Invest. 119(11), 3266-3277 (2009).
156. Fredericksen BL, Smith M, Katze MG, Shi PY, Gale M Jr. The host response to West Nile Virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78(14), 7737-7747 (2004).
157. Gillespie LK, Hoenen A, Morgan G, Mackenzie JM. The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex. J. Virol. 84(20), 10438-10447 (2010).
158. Evans JD, Crown RA, Sohn JA, Seeger C. West Nile virus infection induces depletion of IFNAR1 protein levels. Viral Immunol. 24(4), 253-263 (2011).
159. Lin RJ, Liao CL, Lin E, Lin YL. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J. Virol. 78(17), 9285-9294 (2004).
160. Lin CW, Cheng CW, Yang TC. Interferon antagonist function of Japanese encephalitis virus NS4A and its interaction with DEAD-box RNA helicase DDX42. Virus Res. 137(1), 49-55 (2008).
161. Schuessler A, Funk A, Lazear HM. West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response. J. Virol. 86(10), 5708-5718 (2012).
162. Szretter KJ, Daniels BP, Cho H et al. 2-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and-independent mechanisms of host restriction in vivo. PLoS Pathog. 8(5), e1002698 (2012).
163. Garmashova N, Atasheva S, Kang W, Weaver SC, Frolova E, Frolov I. Analysis of Venezuelan equine encephalitis virus capsid protein function in the inhibition of cellular transcription. J. Virol. 81(24), 13552-13565 (2007).
164. Garmashova N, Gorchakov R, Frolova E, Frolov I. Sindbis virus nonstructural protein nsP2 is cytotoxic and inhibits cellular transcription. J. Virol. 80(12), 5686-5696 (2006).
165. Breakwell L, Dosenovic P, Karlsson Hedestam GB et al. Semliki Forest virus nonstructural protein 2 is involved in suppression of the type I interferon response. J. Virol. 81(16), 8677-8684 (2007).
166. Fros JJ, Liu WJ, Prow NA et al. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J. Virol. 84(20), 10877-10887 (2010).
167. Garmashova N, Gorchakov R, Volkova E, Paessler S, Frolova E, Frolov I. The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff. J. Virol. 81(5), 2472-2484 (2007).
168. Simmons JD, White LJ, Morrison TE et al. Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff. J. Virol. 83(20), 10571-10581 (2009).
169. Yin J, Gardner CL, Burke CW, Ryman KD, Klimstra WB. Similarities and differences in antagonism of neuron alpha/beta interferon responses by Venezuelan equine encephalitis and Sindbis alphaviruses. J. Virol. 83(19), 10036-10047 (2009).
170. Montgomery SA, Johnston RE. Nuclear import and export of Venezuelan equine encephalitis virus nonstructural protein 2. J. Virol. 81(19), 10268-10279 (2007).
171. Barber GN. Host defense, viruses and apoptosis. Cell Death Differ. 8(2), 113-126 (2001).
172. Roulston A, Marcellus RC, Branton PE. Viruses and apoptosis. Annu. Rev. Microbiol. 53, 577-628 (1999).
173. Lee CJ, Liao CL, Lin YL. Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection. J. Virol. 79(13), 8388-8399 (2005).
174. Cao S, Li Y, Ye J et al. Japanese encephalitis Virus wild strain infection suppresses dendritic cells maturation and function, and causes the expansion of regulatory T cells. Virol. J. 8, 39 (2011).
175. Khanna N, Agnihotri M, Mathur A, Chaturvedi UC. Neutrophil chemotactic factor produced by Japanese encephalitis virus stimulated macrophages. Clin. Exp. Immunol. 86(2), 299-303 (1991).
176. Mathur A, Khanna N, Chaturvedi UC. Breakdown of blood-brain barrier by virus-induced cytokine during Japanese encephalitis virus infection. Int. J. Exp. Pathol. 73(5), 603-611 (1992).
177. Ravi V, Parida S, Desai A, Chandramuki A, Gourie-Devi M, Grau GE. Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients. J. Med. Virol. 51(2), 132-136 (1997).
178. Sharma A, Bhomia M, Honnold SP, Maheshwari RK. Role of adhesion molecules and inflammation in Venezuelan equine encephalitis virus infected mouse brain. Virol. J. 8, 197 (2011).
179. Taylor KG, Paessler S. Pathogenesis of Venezuelan equine encephalitis. Vet. Microbiol. 167(1-2), 145-150 (2013).
180. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7(1), 41-53 (2006).
181. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci. 2(10), 734-744 (2001).
182. Griffin DE. Immune responses to RNA-virus infections of the CNS. Nat. Rev. Immunol. 3(6), 493-502 (2003).
183. Burke DS, Morill JC. Levels of interferon in the plasma and cerebrospinal fluid of patients with acute Japanese encephalitis. J. Infect. Dis. 155(4), 797-799 (1987).
184. Ghoshal A, Das S, Ghosh S et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55(5), 483-496 (2007).
185. Singh A, Kulshreshtha R, Mathur A. Secretion of the chemokine interleukin-8 during Japanese encephalitis virus infection. J. Med. Microbiol. 49(7), 607-612 (2000).
186. Suzuki T, Ogata A, Tashiro K et al. Japanese encephalitis virus up-regulates expression of macrophage migration inhibitory factor (MIF) mRNA in the mouse brain. Biochim. Biophys. Acta 1517(1), 100-106 (2000).
187. Winter PM, Dung NM, Loan HT et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J. Infect. Dis. 190(9), 1618-1626 (2004).
188. Swarup V, Ghosh J, Duseja R, Ghosh S, Basu A. Japanese encephalitis virus infection decrease endogenous IL-10 production: Correlation with microglial activation and neuronal death. Neurosci. Lett. 420(2), 144-149 (2007).
189. Taylor K, Kolokoltsova O, Patterson M et al. Natural killer cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis virus in C3H/HeN mice. Vaccine 30(27), 4095-4105 (2012).
190. Chen Y, Hallenbeck JM, Ruetzler C et al. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood Flow Metab. 23(6), 748-755 (2003).